Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.
Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared with wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and exhibit an attenuated response to the HER2 antibody trastuzumab. We investigated herein pathways through which mutant HER2 alters the extracellular environment, potentially leading to drug resistance and the effect of simultaneously targeting HER2 and the tumor cell microenvironment with a therapeutic intent. Expression of mutant HER2 in mammary epithelial cells activated autocrine transforming growth factor (TGF) beta1 signaling through a mechanism involving Rac1 and c-Jun N-terminal kinase-activating protein 1-dependent transcription. Cells transformed by an activating mutant of H-Ras (G12V) also expressed higher TGF-beta1 level through Rac1 activation. In addition, mutant HER2 induced the EGFR ligands TGF-alpha and amphiregulin at the mRNA and protein levels. Vascular endothelial growth factor, a target of the TGF-beta-Smad transcriptional regulation, was also induced as a result of expression of mutant HER2. Inhibition of TGF-beta signaling with the Alk5 small molecule inhibitor LY2109761 reduced growth and invasiveness of cells expressing mutant HER2. Combined inhibition of intracellular and paracrine effects of mutant HER2 by trastuzumab and the EGFR antibody cetuximab were more efficient than single-agent therapies. These data suggest that mutations in oncogenes such as HER2 and Ras not only alter intracellular signaling but also influence on other components of the tumor microenvironment by inducing several pro-invasive growth factors. In turn, these serve as extracellular targets of novel therapeutic strategies directed at both cancer-driving oncogenes and the modified tumor microenvironment.
Wang
S E
SE
Division of Tumor Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA. ewang@coh.org
Yu
Y
Y
Criswell
T L
TL
Debusk
L M
LM
Lin
P C
PC
Zent
R
R
Johnson
D H
DH
Ren
X
X
Arteaga
C L
CL
D002460:Cell Line; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000502:physiology; D009154:Mutation; D009369:Neoplasms / Q000209:etiology / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000502:physiology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction; D018808:Transcription Factor AP-1 / Q000502:physiology; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*; D020830:rac1 GTP-Binding Protein / Q000502:physiology
D066246:ErbB Receptors; D048031:JNK Mitogen-Activated Protein Kinases; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D018808:Transcription Factor AP-1; D053773:Transforming Growth Factor beta1; D042461:Vascular Endothelial Growth Factor A; D020830:rac1 GTP-Binding Protein; C107953:RAC1 protein, human; C508053:ERBB2 protein, human; C501009:HRAS protein, human
Nat Cell Biol. 2002 Jul;4(7):487-94
12105419
J Cell Sci. 2002 Aug 1;115(Pt 15):3193-206
12118074
J Biol Chem. 2001 Dec 28;276(52):48679-92
11606575
Front Biosci. 2001 May 01;6:D685-707
11333208
J Biol Chem. 2004 Jun 4;279(23):24505-13
15044465
Cytokine. 2005 Jan 21;29(2):84-91
15598443
Cancer Res. 2005 Mar 1;65(5):1642-6
15753357
Med Sci Monit. 2004 Apr;10(4):RA89-98
15039660
Nat Rev Cancer. 2007 Mar;7(3):169-81
17318210
Oncogene. 1999 Jan 21;18(3):731-8
9989823
Cancer Cell. 2002 Aug;2(2):127-37
12204533
Cancer Res. 2004 Dec 15;64(24):9002-11
15604265
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1257-62
14739340
Biochem Biophys Res Commun. 1990 Sep 28;171(3):1145-51
2222434
J Biol Chem. 2007 Sep 21;282(38):27713-20
17656362
Mol Cell Biol. 1990 Apr;10(4):1492-7
2108318
Mol Biol Cell. 2001 Jan;12(1):27-36
11160820
EMBO J. 1996 May 15;15(10):2452-67
8665853
Bioorg Med Chem Lett. 2004 Jul 5;14(13):3581-4
15177479
J Biol Chem. 1998 Oct 23;273(43):28238-46
9774445
Oncogene. 2000 Jun 15;19(26):3013-20
10871853
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L525-34
17631612
J Biol Chem. 2000 Feb 25;275(8):5748-53
10681561
Nat Genet. 2001 Oct;29(2):117-29
11586292
Methods. 2003 Jul;30(3):256-68
12798140
Biochemistry. 2005 Feb 22;44(7):2293-304
15709742
Exp Cell Res. 2004 Aug 1;298(1):167-77
15242771
J Am Soc Nephrol. 2000 Nov;11(11):2007-2016
11053476
EMBO J. 2001 Jan 15;20(1-2):128-36
11226163
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6809-14
9618494
Mol Cell Biol. 2005 Jun;25(11):4703-15
15899872
Cancer Res. 1999 Jan 1;59(1):99-106
9892193
Cancer Res. 2006 Oct 1;66(19):9591-600
17018616
J Biol Chem. 1996 Jul 12;271(28):16567-72
8663331
Cancer Cell. 2006 Jul;10(1):25-38
16843263
Cancer Res. 2001 Dec 15;61(24):8887-95
11751413
EMBO J. 1997 Apr 1;16(7):1647-55
9130710
J Biol Chem. 1994 Sep 9;269(36):22817-22
8077234
J Biol Chem. 1997 Jan 17;272(3):1429-32
8999807
Nat Rev Cancer. 2009 Aug;9(8):537-49
19629069
Mol Cell Biol. 2003 Dec;23(23):8691-703
14612410
Nature. 2004 Sep 30;431(7008):525-6
15457249
Cancer Res. 2000 Oct 15;60(20):5879-86
11059786
Cancer Cell. 2003 Jun;3(6):531-6
12842082
Mol Cancer Ther. 2001 Dec;1(2):85-94
12467226
J Biol Chem. 1999 Mar 26;274(13):8865-74
10085130
Int J Cancer. 1999 May 31;81(5):682-7
10328216
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5
12808151
Clin Cancer Res. 2006 Jan 1;12(1):57-61
16397024
Mol Cells. 2006 Apr 30;21(2):167-73
16682809
Mol Cell Biol. 2008 Sep;28(18):5605-20
18625725
J Cell Biol. 2002 Jan 21;156(2):299-313
11790801
J Biol Chem. 2001 Oct 19;276(42):38527-35
11486006
Br J Cancer. 1996 Oct;74(7):1074-80
8855977